SCHEMBL22229863

SCHEMBL22229863

CC(C)CC(N)C(=O)N(CC(=O)O)C(=O)C(N)Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.57
RNPEP Q9H4A4 2/20 0.57
DNPEP Q9ULA0 2/20 0.57
LTA4H P09960 2/20 0.50
ALPI P09923 1/20 0.50
PKM P14618 1/20 0.50
PTGS1 P23219 1/20 0.50
XIAP P98170 1/20 0.50
SLC7A5 Q01650 1/20 0.50
SLC15A1 P46059 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
GPR88 Q9GZN0 1/20 0.45
HPGD P15428 1/20 0.42
SLC6A2 P23975 2/20 0.42
TAAR1 Q96RJ0 2/20 0.42
MAOA P21397 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22229861 1.00 ANPEP (0.57) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL8005620 0.90 ALPI (0.54) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL14691646 0.84 ALPI (0.54) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL28547713 0.83 ACE (0.49) ANPEPRNPEPDNPEPLTA4H
SCHEMBL10908162 0.83 ANPEP (0.45) ANPEPRNPEPDNPEPSLC15A1SLC1A3
SCHEMBL28540563 0.82 ALPI (0.46) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL11151406 0.82 ANPEP (0.56) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL17026707 0.81 ANPEP (0.49) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL28786062 0.81 ANPEP (0.55) ANPEPRNPEPDNPEPLTA4HALPI
SCHEMBL28786054 0.81 ANPEP (0.55) ANPEPRNPEPDNPEPLTA4HALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911348-A1 METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISEASE L & J Bio Co., Ltd. (KR) 2021-11-24 EP claimed
WO-2020150725-A1 METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISEASE L&J BIOSCIENCES INC. (US) 2020-07-23 WO claimed
US-20200230218-A1 METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISEASE L & J Bio Co., Ltd. (KR) 2020-07-23 US claimed
CN-113583178-B Branched sugar-containing polymer-based nanoparticle, and preparation method and application thereof 四川大学华西医院 2023-05-05 CN disclosed
EP-3911348-A1 METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISEASE L & J Bio Co., Ltd. (KR) 2021-11-24 EP disclosed
WO-2020150725-A1 METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISEASE L&J BIOSCIENCES INC. (US) 2020-07-23 WO disclosed
US-20200230218-A1 METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISEASE L & J Bio Co., Ltd. (KR) 2020-07-23 US disclosed
CN-106967062-A The analogs of novel C C 1065 and its conjugate 辛塔佳股份有限公司 2017-07-21 CN disclosed
CN-106749665-A The novel conjugates of the analogs of CC 1065 and bifunctional linker 辛塔佳有限公司 2017-05-31 CN disclosed
CN-106492226-A Tumor-targeting polypeptide anthracycline derivative 武汉大学苏州研究院 2017-03-15 CN disclosed
CN-103118679-B Conjugates of CC-1065 Analogs and Bifunctional Linkers SYNTARGA B.V. (NL) 2016-12-14 CN disclosed
CN-104587484-A POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS REXAHN PHARMACEUTICALS INC 2015-05-06 CN disclosed
CN-102686243-B Polymeric systems for anticancer agent delivery REXAHN PHARMACEUTICALS INC 2015-02-18 CN disclosed
CN-103118679-A Novel conjugates of CC-1065 analogs and bifunctional linkers SYNTARGA BV 2013-05-22 CN disclosed
CN-102686243-A Polymeric systems for anticancer agent delivery REXAHN PHARMACEUTICALS INC 2012-09-19 CN disclosed
CN-102317283-A Novel CC-1065 analogs and conjugates thereof SYNTARGA BV 2012-01-11 CN disclosed
CN-101415679-A Water-soluble CC-1065 analogs and conjugates thereof SINTAGAR B V (NL) 2009-04-22 CN disclosed